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Abstract. Hepatocyte growth factor (HGF) is a key growth 
factor linked to promoting cancer progression and angiogen-
esis. The present study identifies repulsive guidance molecule b 
(RGMb), a bone morphogenetic protein (BMP) co-receptor, as 
a gene whose expression is regulated by HGF and explores the 
potential of RGMb to contribute to the process of angiogen-
esis. Microarray analysis was used to identify HGF responsive 
genes in HECV endothelial cells, identifying RGMb. RGMb 
was subsequently targeted using a ribozyme transgene system 
and its role in angiogenesis assessed using in vitro and in vivo 
assays. The importance of RGMb in pro-angiogenic responses 
to HGF and BMP-7 was also assessed. Microarray analysis 
identified RGMb as a gene upregulated as a result of HGF 
treatment. Knockdown of RGMb, in HECV cells, had minimal 
effects on tubule formation, brought about a general, although 
non-significant increase in cell growth and enhanced cell 
migration. Similarly, no significant effect of RGMb knock-
down was found in vivo using a co-inoculation angiogenesis 
model. Knockdown of RGMb was, however, found to reduce 
the responsiveness of HECV cells to HGF treatment and 
particularly to BMP-7 treatment in regard to the enhanced 
migratory and tubule formation brought about by these treat-
ments in vitro. Our results indicate that RGMb expression can 
be influenced by HGF treatment. Whilst this molecule appears 
to have minimal impact on angiogenic traits individually, it 
demonstrates an involvement in propagating pro-angiogenic 
effects of HGF and particularly BMP-7 and thus, may play a 
role in regulating angiogenic responses to HGF and BMP-7.
Introduction
The field of angiogenesis and its potential as a target to slow 
cancer development is well established and reviewed within 
the literature. Angiogenesis is an essential process required 
for normal physiological events such as wound healing, repro-
duction, development and immunity. However, imbalance 
of this process is often seen in disease states such as cancer 
progression and metastatic spread, where enhanced tumour 
vasculature facilitates rapid tumour growth and provides 
access for metastasising cells (1,2). Numerous pro-angiogenic 
factors have been identified. One such molecule is hepatocyte 
growth factor (HGF), which has long been established as a 
factor that can enhance the aggressive nature of cancer cells 
through its ability to promote pro-metastatic traits such as 
motogenesis, mitogenesis, morphogenesis and angiogenesis 
(3). HGF is able to promote angiogenesis directly through its 
motogenic and morphogenic impact on endothelial cells and 
also indirectly, through its ability to enhance the production 
of other pro-angiogenic factors such as vascular endothelial 
growth factor (VEGF) (3,4). Previous studies have demon-
strated the anti-angiogenic potential of targeting HGF in 
breast and prostate cancer model systems (5,6). The present 
study aimed to identify gene expression in endothelial cells 
that could be regulated by HGF which may subsequently 
contribute to the process of HGF-promoted angiogenesis, 
identifying repulsive guidance molecule b (RGMb) as one 
such molecule.
Following the establishment of RGM as a gene involved 
in the guidance of chick retinal axons (7), three mouse 
orthologues (termed RGMa, RGMb and RGMc) were isolated 
and characterised in separate studies, displaying predomi-
nant expression in the developing and adult nervous system 
(RGMa and RGMb) and skeletal muscles (RGMc) (8-10). An 
independent study, conducted at the same time, also identified 
DRAGON (RGMb) using a genome binding strategy to screen 
for DRG11 regulated genes (11).
RGMb shares structural similarities with the other 
members of the RGM family, including a N-terminal signal 
peptide, a proteolytic cleavage site, a von Willebrand factor 
(vWF) type D domain and a glycophosphatidylinositol (GPI) 
anchor, and is expressed in the developing and adult nervous 
system (7-11). RGMb has also been shown to be involved in 
promoting mouse dorsal root ganglion (DRG) neuron adhe-
sion (11), has been implicated in axonal regeneration after 
injury (12) and in response to spinal cord injury, where it is 
found to be upregulated (13). In addition to its roles in the 
nervous system, RGMb has also been shown to contribute 
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to bone morphogenetic protein (BMP) signalling, where 
it has been identified, together with RGMa and RGMc, as a 
BMP co-receptor (14-17). Additionally, RGMb may play an 
important role in reproduction through the enhancement of 
BMP signalling (18) and a potential role for RGMb has also 
been demonstrated in the immune system where it can inhibit 
IL-6 expression in macrophages through the p38 MAPK 
and ERK1/2 pathway, but not the Smad 1/5/8 pathway, in a 
BMP-ligand-dependent manner (19).
A number of recent studies from our laboratories have 
explored the importance of the members of the RGM family 
in breast and prostate cancer (20-22). RGM levels were 
examined in a breast cancer cohort in conjunction with 
clinical pathological patient data. This study highlighted an 
aberrant expression profile of the RGMs in breast cancer, 
indicating potential links between RGMa and RGMb and 
patient prognosis (20). Further work explored the impact of 
targeting RGMb in breast cancer cell lines in vitro. This study 
demonstrated a potential role for RGMb in breast cancer 
proliferation, matrix-adhesion and migration where targeting 
this molecule enhanced these aggressive traits and implicated 
links with Smad-dependent and Smad-independent pathways 
(22). Similarly, RGMb appears to play a role in prostate cancer 
progression. Knockdown of RGMb in the PC-3 prostate cancer 
cell line enhanced cell growth and migratory rates and also 
increased cell-matrix adhesion. Additionally, RGMb may 
be linked to Smad signalling in this cell line as knockdown 
of RGMb appeared to affect the levels of activated Smad 1 
and 3, and also enhanced ID1 expression (21). Taken together 
these studies suggest important roles for RGMb in breast and 
prostate cancer progression and also imply an involvement in 
BMP and Smad signalling.
In the present study, the potential involvement of RGMb 
was explored in the process of tumour angiogenesis through 
the targeting of RGMb in HECV endothelial cells. Suppression 
of RGMb in HECV cells did not result in significant changes 
to a number of traits associated with the angiogenic process. 
However, we report that suppression of RGMb in HECV 
cells can act to decrease or inhibit the pro-angiogenic effect 
brought about by HGF and, more substantially, BMP-7 on 
tubule formation and migration rates. This study highlights the 
potential importance of RGMb in propagating pro-angiogenic 
effects of HGF and BMP-7.
Materials and methods
Reagents, cell lines and culture conditions. Human HECV 
endothelial cells were purchased from Interlab Cell Line 
Collection (ICLC, Naples, Italy). The MCF-7 breast cancer 
cell line and the PC-3 human prostate cancer cell line were 
purchased from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). Hepatocyte growth factor (HGF) was 
a kind gift from Dr T. Nakamura (Osaka University Medical 
School, Osaka, Japan) and bone morphogenetic protein-7 
(BMP-7) was purchased from Sigma (Dorset, UK). All cells 
were maintained in Dubecco's modified Eagle's medium 
(DMEM) (PAA Laboratories Ltd., Somerset, UK), supple-
mented with penicillin, streptomycin and 10% fetal calf serum 
(PAA Laboratories Ltd.) and incubated at 37˚C, 5% CO2 and 
95% humidity.
Generation of human HECV endothelial cells displaying 
suppressed RGMb expression. RGMb expression was targeted 
in human HECV endothelial cells using a ribozyme transgene 
specifically generated to target and cleave RGMb transcript. 
This methodology has been previously reported (23,24). 
Plasmids containing ribozyme transgenes had previously been 
developed within the laboratory (21,22). Briefly, ribozyme 
transgene sequences were designed based on the predicted 
secondary structure of the RGMb transcript using Zukers 
RNA Mfold program (25) and were synthesised by Invitrogen 
(Paisley, UK). Ribozyme transgenes were subsequently cloned 
into a pEF6/V5-His-TOPO plasmid vector (Invitrogen). Both 
control pEF6 plasmids containing no insert, and plasmids 
containing the RGMb ribozyme transgene were transfected 
into HECV cells using electroporation. Following transfec-
tion, these cells underwent a selection period and subsequent 
verification of RGMb knockdown. Cells containing the 
RGMb ribozyme transgene were termed HECVRGMb KO and 
were compared throughout the study to control HECV cells 
containing closed plasmids alone, termed HECVpEF6.
RNA extraction and reverse transcription-polymerase chain 
reaction (RT-PCR). Cells were grown to confluence in a 
25-cm2 flask before RNA was extracted using total RNA isola-
tion (TRI) reagent (Sigma) in accordance with the supplied 
protocol. RNA was subsequently quantified using a spectro-
photometer (WPA UV 1101, Biotech Photometer, Cambridge, 
UK), standardised to a concentration of 500 ng and used as a 
template to generate cDNA using an iScript cDNA synthesis 
kit (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). 
Following cDNA synthesis, sample quality and uniformity 
was checked, using β-actin primers, before assessing RGMb 
expression using specific primers for RGMb transcript (full 
primer details are shown in Table I). PCR was performed 
using REDTaq® ReadyMix™ PCR Reaction Mix (Sigma). 
The following reaction conditions were set up in a T-Cy 
Thermocycler (Creacon Technologies Ltd., The Netherlands); 
denaturing at 94˚C for 40 sec, annealing at 55˚C for 40 sec 
and extension at 72˚C for 60 sec. PCR was conducted over 
34 cycles following an initial 5-min denaturing step (94˚C) 
and concluded with a final 10-min extension step (72˚C). 
Amplified products were loaded onto an agarose gel, sepa-
rated electrophoretically, stained in ethidium bromide and 
visualised under ultraviolet light.
Microarray analysis of gene expression. Two sets of triplicate 
HECV cell flasks were treated with either 40 ng/ml hepato-
cyte growth factor (HGF) for 4 h or remained untreated and 
RNA extracted as described above using TRI reagent (Sigma). 
Extracted RNA was quantified before being sent to the Cardiff 
University Central Biotechnology Services (CBS) microarray 
facility for labelling and hybridisation to a GeneChip Human 
Genome U133 Plus 2.0 array (Affymetrix UK Ltd., High 
Wycombe, UK).
Quantitative polymerase chain reaction (qPCR). Quantitative 
PCR was used to assess RGMb transcript levels in control and 
transfected cell lines following a previously reported method 
(26,27). Briefly, the iCycler IQ system was used to detect 
and quantify RGMb transcript expression in each sample. 
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Transcript copy number was calculated based on an internal 
standard. Samples were normalised against GAPDH expres-
sion (see Table I for primer details). The Amplifluor system 
(Intergen Inc., New York, NY, USA) was utilised together 
with qPCR Master Mix (ABgene, Surrey, UK). Conditions for 
qPCR were; 15-min initial 95˚C period followed by 60 cycles 
of 95˚C for 15 sec, 55˚C for 60 sec and 72˚C for 20 sec.
SDS-PAGE and western blotting. Protein was extracted from a 
confluent 75-cm2 tissue culture flask. Cells were detached and 
lysed in HCMF buffer containing 0.5% SDS, 1% Triton X-100, 
2 mM CaCl2, 100 µg/ml phenylmethylsulfonyl fluoride, 
1 mg/ml leupeptin, 1 mg/ml aprotinin and 10 mM sodium 
orthovanadate on a rotor wheel for 1 h before removal of 
insolubles through centrifugation at 13,000 g. The Bio-Rad 
DC Protein assay kit (Bio-Rad Laboratories, CA, USA) was 
used to quantify protein levels in the samples. Samples were 
subsequently standardised to 2 mg/ml and diluted in Laemmli 
2X concentrate sample buffer (Sigma) before being boiled 
for 5 min. Samples were loaded onto a 10% acrylamide gel 
and separated electrophoretically. Following separation the 
proteins were blotted onto a Hybond-C Extra nitrocellulose 
membrane (Amersham Biosciences UK Ltd., Bucks, UK) 
and blocked in 10% milk. RGMb expression was detected 
using anti-RGMb antibody (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). In addition to this, GAPDH expres-
sion was also detected, to assess sample uniformity, using 
an anti-GAPDH antibody (Santa Cruz Biotechnology, Inc.). 
Following binding of the primary antibody, the membranes 
were probed with peroxidase conjugated anti-rabbit (RGMb) 
or anti-mouse (GAPDH) secondary antibodies (Sigma). 
Expression was then visualised through the Supersignal 
West Dura Extended Duration substrate chemi-luminescent 
system (Perbio Science UK Ltd., Cramlington, UK) and 
detected using a UVIProChem camera system (UVItec Ltd., 
Cambridge, UK).
In vitro cell growth assay. An in vitro growth assay was used 
to examine the impact of RGMb on cell growth. Cells were 
seeded into 96-well plates at a density of 3,000 cells/well and 
triplicate plates were set up to allow overnight, 3- and 5-day 
incubation periods. Following incubation, the plates were fixed 
in 4% formaldehyde (v/v) and stained with 0.5% (w/v) crystal 
violet. Subsequently, 10% acetic acid (v/v) was used to extract 
the crystal violet stain and cell density was detected through 
spectrophotmeric analysis using a Bio-Tek ELx800 multi-plate 
reader (Bio-Tek Instruments Inc., VT, USA).
In vitro cell migration/wounding assay. Cellular migration 
was assessed using a migration/wounding assay modified 
from a previously described method (28). Briefly, cells were 
cultured to confluence in a 24-well plate before scratching the 
cell monolayer with a pointed plastic pipette tip. Subsequently, 
wound closure, through the migration of cells, was tracked and 
photographed at 15-min interval time-points over a 90-min 
period using an inverted microscope and GXcapture software. 
The distance between the two wound fronts was calculated 
at several consistent points over all the time intervals using 
ImageJ software and average cellular migration calculated.
In vitro tubule formation assay. The potential of RGMb to 
contribute to the process of HECV tubule formation was 
assessed in vitro using a Matrigel endothelial cell tubule 
formation assay modified from a previously reported study 
(29). Briefly, 500 µg of Matrigel, diluted in serum-free 
medium, was seeded into a 96-well plate and incubated for a 
minimum of 40 min to allow setting of the Matrigel. Once set, 
35,000 HECV endothelial cells (HECVpEF6 or HECVRGMb KO 
cells) were seeded onto the Matrigel layer and incubated for 
4-5 h. Tubule formation occurring over the incubation period 
was visualised under low magnification and images captured 
for analysis. Total tubule perimeter per field was subsequently 
quantified using ImageJ software. Where appropriate, treat-
ments consisting of either 40 ng/ml BMP-7 or 40 ng/ml HGF 
were added to the cell medium following seeding.
In vivo tumour development assay. The impact of RGMb 
suppression in vivo was examined using a previously described 
in vivo angiogenesis model (29). Briefly, a 100-µl suspension 
containing 1x106 cancer cells (either MCF-7pEF6 breast cancer 
cells or PC-3pEF6 prostate cancer cells) were subcutaneously 
injected into the left and right flanks of 4-6-week old athymic 
nude mice (CD-1; Charles River Laboratories, Kent, UK) 
together with either 1x106 HECVpEF6 or 1x106 HECVRGMb KO 
cells in a 0.5 mg/ml Matrigel solution. The tumours were 
allowed to develop over the course of the experiment and were 
measured twice weekly using vernier callipers under sterile 
conditions. The mice were housed in filter top units and were 
treated humanely in accordance with United Kingdom Home 
Office and the United Kingdom Coordinating Committee on 
Cancer Research (UKCCCR) guidelines. All in vivo work 
undertaken in this study was conducted under the project 
license (PPL 30/2591) of the British Home Office. Animals 
were dispatched humanely if severity limits were reached or at 
the experimental end point using a schedule 1 method. Tumour 
Table I. Primers used in the study.
Primer set Sense Anti-sense
β-actin  probe ATGATATCGCCGCGCTCG CGCTCGGTGAGGATCTTCA
RGMb probe GGATCCAGTGCTACTGCTAC GTAAAGTTGGCATCACCAGT
GAPDH qPCR CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGAT GACCCTTTTG
RGMb qPCR TTCAGTTCAAGTGACAAACG ACTGAACCTGACCGTACATCATCTGTCACAGCTTGGTA
ACTGAACCTGACCGTACA indicates Z sequence.
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volume was calculated for each time-point using the following 
formula: Tumour volume = 0.523 x width2 x length.
Statistical analysis. The Minitab 14 statistical package was 
used to test for statistical differences between RGMb knock-
down HECV cells and the pEF6 vector control HECV cells 
using a two sample, two tailed t-test. Experimental procedures 
were repeated a minimum of three independent times. Data 
represents mean values ± SEM, values of p<0.05 were regarded 
as statistically significant.
Results
Hepatocyte growth factor can regulate repulsive guidance 
molecule b expression. A microarray study was conducted 
to examine how gene expression within the HECV human 
endothelial cell line was affected following 4-h treatment 
with 40 ng/ml HGF. Treatment with HGF caused a range of 
differential gene expression within this endothelial cell line. 
Repulsive guidance molecule b (RGMb) expression was 
significantly increased following HGF treatment (p=0.004 
vs. untreated control cells) and the expression of RGMb was 
found to be enhanced ~2.5 times by HGF treatment (Fig. 1).
Suppression of RGMb expression using a ribozyme transgene 
system. RGMb expression was successfully knocked down 
following transfection of HECV cells with a pEF6 plasmid 
containing a ribozyme transgene specifically targeted to 
RGMb transcript. Reduced RGMb transcript expression can 
be seen in the HECVRGMb KO cells in comparison to empty 
plasmid control HECVpEF6 cells using RT-PCR and quantita-
tive PCR (Fig. 2A and B). Similarly, reduced RGMb protein 
levels were observed, using western blot analysis, in HECV 
cells transfected with the ribozyme transgene in comparison 
to control cells (Fig. 2C).
Impact of RGMb suppression on endothelial in vitro cell 
traits. Following successful targeting of RGMb, the impact of 
this knockdown on endothelial cell functions was examined 
in vitro. Knockdown of RGMb did not significantly alter the 
rate of cell growth in HECV cells (Fig. 3A), however, the 
suppression did tend to increase growth rates over both a 3- and 
5-day incubation period (HECVpEF6 vs. HECVRGMb KO, p=0.08, 
3-day incubation; 5-day incubation p=0.15). Suppression of 
RGMb appeared to impact later stages of HECV migration 
(Fig. 3B), with enhanced levels of migration being observed 
in HECVRGMb KO cells compared to HECVpEF6 control cells 
at 75 min (p=0.069) and 90 min (p=0.035). Our results also 
suggest that knockdown of RGMb has little effect on HECV 
tubule formation and thus angiogenic potential in vitro (Fig. 3C 
and D), where using this angiogenic assay little difference 
in levels of tubule formation was observed between control 
HECVpEF6 and HECVRGMb KO cells. No significant difference 
between quantified total tubule perimeter levels was seen 
between HECVpEF6 and HECVRGMb KO cells (p=0.813).
Suppression of RGMb has limited impact in vivo. We next 
investigated the role of RGMb knockdown using an in vivo 
angiogenesis model, whereby endothelial cells, either control 
or RGMb suppressed, were inoculated alongside cancer cells 
to examine their potential to impact on the development of 
the cancer cell tumour. This was tested in a prostate cancer 
model (Fig. 4A), where PC-3 cells were used and a breast 
Figure 1. Treatment of HECV endothelial cells with HGF upregulates RGMb 
expression. Microarray analysis demonstrated a significant increase in RGMb 
expression in triplicate samples treated with 40 ng/ml HGF in comparison to 
untreated samples (p=0.004).
Figure 2. Verification of RGMb suppression in HECV cells. RGMb was suc-
cessfully targeted and knocked down in HECV cells through transfection 
with the RGMb specific ribozyme transgene. Knockdown in HECVRGMb KO 
cells was confirmed, in comparison to the plasmid control HECVpEF6 cells, 
at both the transcript level, using RT-PCR (a) and qPCR (b), and the protein 
level, using western blot analysis (c). Error bars represent SEM.
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cancer model (Fig. 4B), where MCF-7 cells were used. In both 
cases little difference was observed between tumour develop-
ment involving control HECVpEF6 or HECVRGMb KO cells, with 
neither model yielding statistically different levels of tumour 
development (p>0.05 in both cases).
RGMb suppression can limit pro-angiogenic effects of HGF. 
Following on from establishing the involvement of RGMb 
in traits associated with the angiogenic cascade, we next 
looked to identify its importance in how HGF could enhance 
these angiogenic traits (Fig. 5). Following treatment with 
40 ng/ml HGF, a significant increase was seen in HECVpEF6 cell 
migration rates (Fig. 5A). Treatment with HGF significantly 
enhanced the distance migrated by HECVpEF6 cells following 
60- (p=0.02), 75- (p=0.02) and 90-min (p=0.001) time-points. 
In contrast, when RGMb was targeted in this endothelial cell 
line, treatment with 40 ng/ml HGF did not appear to have 
as great a pro-migratory effect (Fig. 5B). General increases 
in migration rates were observed in the later time-points of 
the experiment but these were not found to be statistically 
significant (p=0.44 at 60 min, p=0.24 at 75 min and p=0.23 
at 90 min). Similar trends were observed with tubule forma-
tion capacity (Fig. 5C and D). In keeping with its established 
pro-angiogenic role, HGF significantly enhanced the level of 
tubule formation in this in vitro angiogenic assay in the control 
HECVpEF6 cell line (untreated HECVpEF6 vs. 40 ng/ml HGF 
treated HECVpEF6, p=0.001). However, when HECVRGMb KO 
cells were treated with HGF the increase in tubule formation 
was not as great and no significant difference was observed 
between untreated and 40 ng/ml HGF treated HECVRGMb KO 
cells (p=0.210).
RGMb suppression inhibits BMP-7 pro-angiogenic response. 
As the RGM family have been identified as BMP co-receptors, 
we also examined the impact of suppressing RGMb expression 
on HECV BMP promoted responses, in particular BMP-7. In 
control HECVpEF6 cells, treatment with BMP-7 caused a notable 
increase in cell migration (Fig. 6A), which was apparent in 
the later stages of the experiment (untreated HECVpEF6 vs. 
40 ng/ml BMP-7 treated HECVpEF6; 60 min, p=0.037; 75 min, 
p=0.144; 90 min, p=0.089). In contrast to this, suppression 
of RGMb in HECV endothelial cells removed the migratory 
response of this cell line to BMP-7 with very little difference 
being observed between the migration pattern of HECVRGMb KO 
cells treated with 40 ng/ml BMP-7 and control, untreated 
HECVRGMb KO cells (Fig. 6B). A similar trend was also apparent 
in the tubule formation experiments (Fig. 6C and D). In control 
HECVpEF6 cells, treatment with 40 ng/ml BMP-7 caused an 
increase in the tubule formation potential of these endothelial 
cells and treatment of HECVpEF6 cells with 40 ng/ml BMP-7 
brought about a significant increase in total tubule perimeter 
(p=0.005). As with cell migration, suppression of RGMb in 
HECV cells removed the cells responsiveness to BMP-7 treat-
ment and no significant difference in total tubule perimeter 
was observed between untreated HECVRGMb KO and 40 ng/ml 
BMP-7 treated HECVRGMb KO cells (p=0.986).
Figure 3. In vitro impact of RGMb on HECV cell function. Knockdown of RGMb tended to enhance cell growth in comparison to the HECVpEF6 control cells 
over 3- and 5-day incubation periods, though this did not reach significant levels (a). Knockdown of RGMb did significantly enhance migrational rates in 
comparison to HECVpEF6 cells following 90 min (b), but was not seen to have any impact on angiogenic potential in a Matrigel tubule formation assay (c and d). 
Representative images are shown in (c). Error bars represent SEM; *p<0.05.
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Figure 4. In vivo impact of RGMb knockdown. A co-inoculation angiogenesis assay was used to compare the ability of HECVpEF6 control cells and HECVRGMb KO 
cells to contribute to tumour development, in CD-1 athymic nude mice, of PC-3 prostate cancer (a) and MCF-7 breast cancer (b) cells in vivo. No significant 
differences were seen in the development of PC-3 or MCF-7 tumour development between those co-inoculated with HECVpEF6 and those inoculated with 
HECVRGMb KO. Error bars represent SEM.
Figure 5. RGMb knockdown can suppress HGF mediated pro-angiogenic traits in HECV endothelial cells. (a) HGF treatment significantly enhanced HECVpEF6 
cell migration compared to untreated HECVpEF6 cells. In contrast to this treatment of HECVRGMb KO cells with HGF, whilst bringing about a general increase in 
migration rates, was not found to have any significant impact in comparison to untreated HECVRGMb KO cells (b). Similarly, treatment of HECVpEF6 cells with 
HGF could significantly enhance tubule formation in an in vitro Matrigel tubule formation assay in comparison to untreated HECVpEF6 control cells but only 
brought about a reduced, non-significant response in HECVRGMb KO cells compared to untreated HECVRGMb KO cells (c and d). Representative images are shown 
in (c). Error bars represent SEM; *p<0.05.
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Discussion
In the present study we used a microarray approach to iden-
tify gene expression that could be regulated by HGF and 
identified RGMb as a gene whose expression was enhanced 
~2.5-fold following 4-h treatment with 40 ng/ml HGF. This 
data implicates RGMb as a HGF regulated gene in HECV 
human endothelial cells. Subsequently, we examined the 
potential of RGMb to impact on angiogenesis related factors 
in vitro and in vivo. RGMb expression was successfully 
targeted, using a ribozyme transgene system, in HECV cells 
resulting in a strong reduction in RGMb transcript and protein 
levels. Suppression of RGMb alone, however, did not appear to 
have substantial effects on HECV cells and only appeared to 
significantly influence cell migratory rates in the later stages 
of a scratch wounding migration assay. In vitro growth and 
tubule formation revealed no significant differences in RGMb 
suppressed compared to control HECV cells, though growth 
rates were elevated somewhat in the HECVRGMb KO cell line. 
Similar trends were observed in an in vivo model involving the 
co-inoculation of HECV endothelial cells and breast or pros-
tate tumour cells suggesting that, solely, RGMb may contribute 
little to the angiogenic process. The results observed here 
regarding the role of RGMb in the basic function of endothe-
lial cells are somewhat in line with previous work from our 
laboratories focusing on breast and prostate cancer. In both 
of these studies, knockout of RGMb resulted in enhanced 
migratory rates of prostate (PC-3) and breast (MDA-MB-231, 
MCF-7) cancer cell lines and enhanced cell growth rates in 
PC-3 and MDA-MB-231 cells, though not MCF-7 cells (21,22). 
Together with our results the data suggest RGMb is involved in 
the regulation of cell migration and growth of certain cancer 
and to some extent endothelial cells.
Despite RGMb having minimal effect independently on 
these angiogenic traits, a role for RGMb was discovered in 
facilitating pro-angiogenic effects brought about by HGF. 
HECV cells displaying reduced RGMb expression were less 
able to respond in a pro-angiogenic manner to HGF treat-
ment, and angiogenic traits such as cell migration and tubule 
formation capacity were not significantly enhanced by HGF 
treatment in HECVRGMb KO cells as they were in HGF treated 
HECVpEF6 cells. Taken together with the establishment of 
HGFs capacity to regulate RGMb gene expression, our data 
provides evidence that RGMb may act as a potential mecha-
nism to bring about HGFs pro-angiogenic effects.
In addition to examining the potential of RGMb to 
contribute to progressing the pro-angiogenic effects of HGF, 
and in light of the established roles of members of the RGM 
Figure 6. RGMb knockdown inhibits BMP-7-mediated pro-angiogenic response in HECV endothelial cells. (a) BMP-7 treatment partially enhanced the 
cell migration rates of HECVpEF6 control cells, resulting in significant or close to significant differences compared to untreated HECVpEF6 cells following 
60-min incubation onwards. In contrast, virtually no deviations were observed between untreated HECVRGMb KO cells and those treated with BMP-7 (b). 
Similar trends were observed in the Matrigel tubule formation assays where treatment with BMP-7 could enhance tubule formation levels of HECVpEF6 
cells, in comparison to untreated HECVpEF6 cells, but again demonstrated virtually no effects on HECVRGMb KO cells treated with BMP-7 compared to those 
that remained untreated (c and d). Representative images are shown in (c). Error bars represent SEM; *p<0.05.
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family as BMP co-receptors (14-17) we also aimed to explore 
the potential of RGMb to facilitate the pro-angiogenic effects 
of BMP-7. The BMPs are members of the transforming 
growth factor β (TGF-β) family, exerting their signals through 
type I and II transmembrane serine/theronine kinase recep-
tors to influence a plethora of biological processes including 
angiogenesis. BMP-2, -4, -6 and -7 have been implicated in 
both the activation phase, where they can enhance endothe-
lial cell proliferation and migration, and also the maturation 
phase, where they can influence vascular smooth muscle 
cells (reviewed in refs. 30 and 31). Interestingly, suppression 
of RGMb in HECV cells, whilst reducing the pro-angiogenic 
effects of HGF, was also found to substantially inhibit BMP-7 
promoted cell migration and tubule formation. The pro-migra-
tory impact of BMP-7 itself was not as great as that of HGF, 
a well established motogen (3), with BMP-7 enhancement of 
migration rates not showing as significant increases in migra-
tion rates of control HECV cells as HGF. However, suppression 
of RGMb in HECV cells could substantially remove any 
pro-migratory effect of BMP-7 with migration rates showing 
similar levels to that of untreated HECVRGMb KO controls. In 
keeping with this trend a similar pattern was seen on tubule 
formation capacity. In control HECVpEF6 cells, treatment with 
40 ng/ml BMP-7 brought about a significant increase in tubule 
formation levels. Suppression of RGMb again inhibited this 
pro-tubule formation effect with mean tubule formation levels 
comparable to untreated controls and no significant difference 
being observed between untreated and treated HECVRGMb KO 
cells. The data appear to be in line with the current literature, 
identifying RGMs as BMP co-receptors (14-17) and this study 
demonstrates the importance of this in contributing to the 
angiogenic process.
It is noteworthy that HGF has previously been demonstrated 
to enhance the expression of BMP-7 and the expression of the 
BMPR-IB and BMPR-II BMP receptors in prostate cancer 
cells (32,33). A similar trend has also been observed briefly 
in the HECV endothelial cells used in this study, where treat-
ment with HGF was found, using qPCR, to enhance BMP-7 
levels in a time course experiment (data not shown). It may be 
worth considering that crosstalk between these two pathways 
may present a partial means to explain the results obtained in 
our study. A weaker response was apparent, particularly in the 
tubule formation experiments, in RGMb knockdown cells to 
BMP-7 rather than HGF. It is possible that HGF may partially 
act to enhance BMP signalling, possibly through enhancement 
of BMP-7 and/or BMP receptor levels in these cells, which 
in turn could be interrupted through RGMb suppression. 
This however, requires further scientific examination before 
conclusions can be drawn.
Other studies conducted in our laboratories have implicated 
members of the RGM family in breast and prostate cancer. 
Knockdown of RGMb was found to enhance PC-3 prostate 
cancer cell growth, cell-matrix adhesion and migration. 
Additionally, knockdown of RGMb enhanced levels of acti-
vated Smad 3 and ID1 expression, a trend that was increased 
through treatment with BMP-7, but generally reduced activated 
levels of Smad 1 (21). Similar to the prostate cancer study, 
knockdown of RGMb in MDA-MB-231 breast cancer cells 
was also found to enhance cell growth, matrix adhesion and 
migration. Knockdown of RGMb was also found to facilitate 
survival from apoptosis under serum starvation. Alterations, 
following RGMb knockdown, were observed in the regula-
tion of c-myc, caspase-3, SNAIL, TWIST, FAK and paxillin. 
This study also implicated RGMb knockdown to contribute 
to the Smad-dependent pathway, enhancing levels of acti-
vated Smad 1 and 3 in untreated cells, with greater responses 
seen following BMP-7 treatment and a switching to Smad 1 
activation following inhibition of Smad 3, whereas phosphory-
lation of JNK, ILP and TAK was inhibited following RGMb 
knockdown suggesting suppression of the Smad-independent 
pathway (22).
In the present study, knockdown of RGMb in human 
endothelial cells enhanced migration and also appeared to 
suppress the pro-angiogenic response to HGF and BMP-7. 
Taken together, this suggests that, while loss of RGMb may 
enhance aggressive traits in prostate and breast cancer cells, 
suppression of RGMb may also act to suppress HGF and 
BMP-7 mediated tumour angiogenesis. Also, in contrast to the 
previous prostate and breast cancer studies, where treatment 
of RGMb knockdown cells with BMP-7 enhances activity of 
Smad 1 or 3, our present study implies that in HECV cells 
RGMb knockdown may act to suppress signalling resulting 
from BMP-7 treatment. RGMb has been identified as a BMP 
co-receptor, directly binding BMP-2, and -4 but not -7 or 
TGF-β ligands and associating with the ALK2, 3 and 6, BMP 
type I and the ActRII and ActRIIB BMP type II receptors 
(14). Since its discovery a number of studies have shown this 
molecule to play a role in enhancing BMP signalling (12, 14, 
18). However, RGMb has also demonstrated the ability to 
inhibit BMP signalling in C2C12 myoblasts (34). These obser-
vations, taken with the data presented here and the previous 
prostate and breast cancer studies (21,22) suggest a complex 
relationship between RGMb and BMP signalling. Further 
scientific study is required to establish fully the downstream 
effectors of BMP-7 and HGF treatment in endothelial cells. 
The data presented in this study have, for the first time, raised 
the implication that RGMb may play some complex role(s) 
in the process of tumour angiogenesis mediated by HGF and 
BMP-7 and further links RGMb to tumour progression.
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